JP7751381B2 - Ｇｌｐ－２誘導体の持続型結合体 - Google Patents
Ｇｌｐ－２誘導体の持続型結合体Info
- Publication number
- JP7751381B2 JP7751381B2 JP2020517828A JP2020517828A JP7751381B2 JP 7751381 B2 JP7751381 B2 JP 7751381B2 JP 2020517828 A JP2020517828 A JP 2020517828A JP 2020517828 A JP2020517828 A JP 2020517828A JP 7751381 B2 JP7751381 B2 JP 7751381B2
- Authority
- JP
- Japan
- Prior art keywords
- glp
- derivative
- conjugate
- group
- immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023111438A JP2023138505A (ja) | 2017-09-28 | 2023-07-06 | Ｇｌｐ－２誘導体の持続型結合体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170126577 | 2017-09-28 | ||
| KR10-2017-0126577 | 2017-09-28 | ||
| PCT/KR2018/011586 WO2019066586A1 (ko) | 2017-09-28 | 2018-09-28 | 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023111438A Division JP2023138505A (ja) | 2017-09-28 | 2023-07-06 | Ｇｌｐ－２誘導体の持続型結合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534840A JP2020534840A (ja) | 2020-12-03 |
| JP2020534840A5 JP2020534840A5 (enExample) | 2023-07-24 |
| JP7751381B2 true JP7751381B2 (ja) | 2025-10-08 |
Family
ID=65902619
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517828A Active JP7751381B2 (ja) | 2017-09-28 | 2018-09-28 | Ｇｌｐ－２誘導体の持続型結合体 |
| JP2023111438A Pending JP2023138505A (ja) | 2017-09-28 | 2023-07-06 | Ｇｌｐ－２誘導体の持続型結合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023111438A Pending JP2023138505A (ja) | 2017-09-28 | 2023-07-06 | Ｇｌｐ－２誘導体の持続型結合体 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11530249B2 (enExample) |
| EP (1) | EP3689898B1 (enExample) |
| JP (2) | JP7751381B2 (enExample) |
| KR (2) | KR102681143B1 (enExample) |
| CN (1) | CN111433221B (enExample) |
| AR (1) | AR113258A1 (enExample) |
| AU (1) | AU2018339210B2 (enExample) |
| BR (1) | BR112020006189A2 (enExample) |
| CA (1) | CA3084326A1 (enExample) |
| EA (1) | EA202090571A1 (enExample) |
| IL (1) | IL273528B2 (enExample) |
| MX (1) | MX2020004453A (enExample) |
| PH (1) | PH12020550105A1 (enExample) |
| SA (1) | SA520411644B1 (enExample) |
| SG (1) | SG11202002563WA (enExample) |
| TW (2) | TWI795443B (enExample) |
| WO (1) | WO2019066586A1 (enExample) |
| ZA (1) | ZA202001888B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202111311WA (en) | 2019-06-14 | 2021-12-30 | Zealand Pharma As | Pharmaceutical parenteral composition of dual glp1/2 agonist |
| JP7846622B2 (ja) * | 2019-12-24 | 2026-04-15 | ハンミ ファーマシューティカル カンパニー リミテッド | Ｇｌｐ－２又はその結合体を含む、代謝性骨疾患の予防又は治療用薬学的組成物 |
| EP4126004A1 (en) | 2020-03-30 | 2023-02-08 | Zealand Pharma A/S | Agonist combination |
| WO2021201654A1 (ko) | 2020-04-03 | 2021-10-07 | 한미약품 주식회사 | Glp-2 유도체 또는 이의 지속형 결합체를 포함하는 방사선요법, 화학요법, 또는 이들의 조합으로 유발된 점막염의 예방 또는 치료용 약학적 조성물 |
| MX2022014671A (es) * | 2020-05-22 | 2023-02-13 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de conjugado de glp-2 de accion prolongada. |
| BR112022025141A2 (pt) | 2020-06-09 | 2023-04-25 | Vectivbio Ag | Fabricação, formulação e dosagem de apraglutida |
| KR20220092446A (ko) * | 2020-12-24 | 2022-07-01 | 한미약품 주식회사 | 단장증후군의 예방 또는 치료를 위한 인슐린 분비 펩타이드 및 glp-2의 병용 요법 |
| JP2025513345A (ja) * | 2022-04-18 | 2025-04-24 | ハンミ ファーマシューティカル カンパニー リミテッド | 腸疾患の予防又は治療のためのＧＬＰ－２と、インスリン分泌ペプチド、ＴＮＦα抑制剤、又はその両方の併用療法 |
| CN120435309A (zh) | 2022-12-23 | 2025-08-05 | 韩美药品株式会社 | 含有glp-2衍生物或其长效缀合物的用于预防或治疗移植物抗宿主病的药物组合物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004532819A (ja) | 2001-02-16 | 2004-10-28 | コンジュケム，インコーポレーテッド | 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド２（ｇｌｐ−２） |
| JP2015503554A (ja) | 2011-12-30 | 2015-02-02 | ハンミ サイエンス カンパニー リミテッドＨａｎｍｉ Ｓｃｉｅｎｃｅｃｏ．，Ｌｔｄ． | 免疫グロブリンフラグメントを用いた部位特異的ｇｌｐ−２薬物結合体 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| US20090238838A1 (en) * | 2003-11-13 | 2009-09-24 | Hanmi Pharm. Ind. Co. Ltd. | Insulinotropic peptide conjugate using an immunoglobulin fc |
| HRP20060362A2 (en) * | 2004-04-23 | 2007-03-31 | Conjuchem Biotechnologies Inc. | Method for the purification of albumin conjugates |
| UA95235C2 (en) * | 2005-05-04 | 2011-07-25 | Зииланд Фарма А/С | Glucagon-like-peptide-2 (glp-2) analogues |
| JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| US20110171164A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of glp-2-like peptides |
| KR101746686B1 (ko) * | 2010-10-26 | 2017-06-15 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―２（ｇｌｐ―２）약물 결합체 |
| JP6206972B2 (ja) * | 2011-09-12 | 2017-10-04 | アムニクス オペレーティング インコーポレイテッド | グルカゴン様ペプチド−２組成物およびその作製法および使用法 |
-
2018
- 2018-09-28 EA EA202090571A patent/EA202090571A1/ru unknown
- 2018-09-28 SG SG11202002563WA patent/SG11202002563WA/en unknown
- 2018-09-28 AR ARP180102806A patent/AR113258A1/es unknown
- 2018-09-28 BR BR112020006189-1A patent/BR112020006189A2/pt unknown
- 2018-09-28 IL IL273528A patent/IL273528B2/en unknown
- 2018-09-28 EP EP18860379.9A patent/EP3689898B1/en active Active
- 2018-09-28 CN CN201880074180.4A patent/CN111433221B/zh active Active
- 2018-09-28 TW TW107134398A patent/TWI795443B/zh active
- 2018-09-28 MX MX2020004453A patent/MX2020004453A/es unknown
- 2018-09-28 KR KR1020180116327A patent/KR102681143B1/ko active Active
- 2018-09-28 WO PCT/KR2018/011586 patent/WO2019066586A1/ko not_active Ceased
- 2018-09-28 TW TW110126453A patent/TWI794897B/zh active
- 2018-09-28 CA CA3084326A patent/CA3084326A1/en active Pending
- 2018-09-28 JP JP2020517828A patent/JP7751381B2/ja active Active
- 2018-09-28 AU AU2018339210A patent/AU2018339210B2/en active Active
-
2020
- 2020-03-19 PH PH12020550105A patent/PH12020550105A1/en unknown
- 2020-03-24 ZA ZA2020/01888A patent/ZA202001888B/en unknown
- 2020-03-27 US US16/832,634 patent/US11530249B2/en active Active
- 2020-03-28 SA SA520411644A patent/SA520411644B1/ar unknown
-
2022
- 2022-04-14 US US17/721,048 patent/US20220251164A1/en active Pending
- 2022-11-02 US US17/979,531 patent/US20230090790A1/en active Pending
-
2023
- 2023-07-06 JP JP2023111438A patent/JP2023138505A/ja active Pending
-
2024
- 2024-01-22 KR KR1020240009740A patent/KR102681144B1/ko active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004532819A (ja) | 2001-02-16 | 2004-10-28 | コンジュケム，インコーポレーテッド | 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド２（ｇｌｐ−２） |
| JP2015503554A (ja) | 2011-12-30 | 2015-02-02 | ハンミ サイエンス カンパニー リミテッドＨａｎｍｉ Ｓｃｉｅｎｃｅｃｏ．，Ｌｔｄ． | 免疫グロブリンフラグメントを用いた部位特異的ｇｌｐ−２薬物結合体 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7751381B2 (ja) | Ｇｌｐ－２誘導体の持続型結合体 | |
| KR102413691B1 (ko) | 신규한 인슐린 아날로그 및 이의 용도 | |
| KR102395856B1 (ko) | 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도 | |
| KR101968344B1 (ko) | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 | |
| JP2022130723A (ja) | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体のすべてに活性を有する三重活性体の持続型結合体 | |
| RU2733544C2 (ru) | Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение | |
| JP6336394B2 (ja) | 生理活性ポリペプチド複合体の製造方法 | |
| JP6465817B2 (ja) | インスリン位置特異的結合体 | |
| TWI798209B (zh) | 對胰島素受體有降低親和性之胰島素類似物之接合物及其用途 | |
| JP2023538236A (ja) | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体を含む血圧降下用薬学組成物 | |
| EA047924B1 (ru) | Конъюгаты производных glp-2 пролонгированного действия | |
| HK40024582A (en) | Long-acting conjugate of glucagon-like peptide-2 (glp-2) derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210927 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220826 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220907 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221206 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230306 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20230706 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230712 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20230908 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250717 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250813 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250926 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7751381 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |